Stocklytics Platform
Asset logo for symbol INSM
Insmed
INSM62
$76.71arrow_drop_down0.41%-$0.32
Asset logo for symbol INSM
INSM62

$76.71

arrow_drop_down0.41%

Income Statement (INSM)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
EBIT-$157.40M-$161.36M-$139.56M-$224.16M-$157.65M
EBITDA-$154.55M-$158.62M-$136.80M-$221.59M-$147.00M
gross Profit$56.78M$65.25M$62.36M$60.63M$51.38M
NET Income-$157.09M-$186.06M-$158.93M-$244.80M-$159.76M
total Revenue$75.50M$83.69M$79.07M$77.22M$65.21M

Balance Sheet (INSM)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
cash Equivalents-----
net Debt$774.96M$721.62M$710.08M$574.76M$215.80M
stockholders Equity-$464.80M-$331.92M-$289.35M-$155.74M-$44.65M
total Assets$1.15B$1.32B$1.32B$1.43B$1.51B
total Debt$1.37B$1.20B$1.19B$1.18B$1.18B
total Liabilities$1.62B$1.66B$1.61B$1.59B$1.56B

Cash Flow (INSM)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
financing Cash Flow$3.02M$123.26M$1.24M$44.32M-$399.00K
free Cash Flow-$188.71M-$132.97M-$139.18M-$127.67M-$149.70M
investing Cash Flow----$274.15M$41.60M
operating Cash Flow-$184.03M-$130.81M-$136.33M-$122.79M-$146.30M

Insmed (INSM) Financials

Insmed Inc (INSM) is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company's financials provide important insights into its performance and financial health. Let's take a closer look at Insmed's income statement, EBIT (earnings before interest and taxes), EBITDA (earnings before interest, taxes, depreciation, and amortization), gross profit, net income from stockholders, total revenue, balance sheet, cash equivalents, net debt, stockholders equity, total assets, total debt, total liabilities, cash flow, financing cash flow, free cash flow, investing cash flow, and operating cash flow.

Starting with the income statement, it shows Insmed's revenue and expenses over a specific period. The EBIT represents the company's earnings before subtracting interest and taxes, providing a measure of its operating profitability. EBITDA further adds back depreciation and amortization expenses to better reflect the cash flow. Gross profit is the difference between revenue and the cost of goods sold, indicating the profitability of the company's core operations. Net income from stockholders refers to the amount left for shareholders after all expenses and taxes have been deducted.

Moving on to total revenue, it represents the sum of all sales made by Insmed during a given period. The balance sheet is a snapshot of the company's financial position, including its assets, liabilities, and stockholders' equity. Cash equivalents refer to highly liquid assets that can be readily converted into cash. Net debt is the difference between a company's total debt and its cash and cash equivalents. Stockholders' equity represents the residual value of assets after deducting liabilities.

Total assets encompass all the resources owned by Insmed, including both tangible and intangible assets. Meanwhile, total debt is the sum of the company's short-term and long-term debt. Total liabilities include all obligations and debts owed by Insmed. The cash flow statement tracks the movement of cash in and out of the company. Financing cash flow represents the cash generated or used from financing activities, such as issuing or repurchasing stock and borrowing or repaying debt.

Free cash flow is a measure of the company's ability to generate cash after accounting for capital expenditures. Investing cash flow shows the cash flows related to the acquisition and disposal of long-term assets. Finally, operating cash flow refers to the cash generated from the company's day-to-day operations. Insmed's financials provide valuable information for investors and analysts to assess its performance, liquidity, and overall financial health.

add Insmed  to watchlist

Keep an eye on Insmed

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level